TG Therapeutics, Inc. Announces Investigational New Drug (IND) for TGTX-1101, Receives Clearance by the FDA to Commence Clinical Trials in the U.S.
Published: May 15, 2012
NEW YORK, May 14, 2012 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (the "Company") - announced today that the U.S. Food and Drug Administration ("FDA") has cleared its Investigational New Drug Application ("IND") for TGTX-1101, also known as ublituximab, a novel third generation chimeric monoclonal antibody targeting a unique epitope on the CD20 antigen found on B lymphocytes. The Company is now permitted to commence its Phase 1/2 clinical trial in patients with B-cell Lymphomas, which it plans to do this summer.